Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 24 , ISSUE 10 ( October, 2020 ) > List of Articles

EDITORIAL

Coronavirus Disease 2019 Treatment: It is Time for Stewardship!

Keywords : Adverse drug reactions, Coronavirus disease 2019, Coronavirus disease 2019 pandemic, COVID pneumonia, Emergency department, Pharmacovigilance, Therapeutic option, Trigger tool

Citation Information : Coronavirus Disease 2019 Treatment: It is Time for Stewardship!. Indian J Crit Care Med 2020; 24 (10):895-896.

DOI: 10.5005/jp-journals-10071-23622

License: CC BY-NC 4.0

Published Online: 30-10-2020

Copyright Statement:  Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract


PDF Share
  1. COVID-19-Related Guidance Documents for Industry, FDA Staff, and Other Stakeholders, Updated September 14, 2020. Available at: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-related-guidance-documents-industry-fda-staff-and-other-stakeholders (accessed on 21st September 2020).
  2. Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc 2012;87(10):982–990. DOI: 10.1016/j.mayocp.2012.04.017.
  3. Le Jeunne C, Billon N, Dandon A, Berdaï D, Adgibi Y, Bergmann JF, et al. Off-label prescriptions: how to identify them, frame them, announce them and monitor them in practice? Therapie 2013;68(4):225–239. DOI: 10.2515/therapie/2013041.
  4. Bunnik EM, Aarts N, van de Vathorst S. Little to lose and no other options: ethical issues in efforts to facilitate expanded access to investigational drugs. Health Policy 2018;122(9):977–983. DOI: 10.1016/j.healthpol.2018.06.005.
  5. Goyal PK, Mathur R, Medhi B. Understanding the challenges and ethical aspects of compassionate use of drugs in emergency situations. Indian J Pharmacol 2020;52(3):163–171. DOI: 10.4103/ijp.IJP_665_20.
  6. Gota V, Divatia JV. Off-label use of drugs: An evil or a necessity? Indian J Anaesth 2015;59(12):767–768. DOI: 10.4103/0019-5049.171555.
  7. Oberoi SS. Regulating off-label drug use in india: the arena for concern. Perspect Clin Res 2015;6(3):129–133. DOI: 10.4103/2229-3485.159935.
  8. Maddani SS, Chaudhuri S, Deepa HC, Amara V. A multicenter questionnaire-based study to know the awareness and medical treatment plan of physicians involved in the management of COVID-19 patients. Indian J Crit Care Med 2020;24(10):919–925.
  9. World Health Organization, “Solidarity” clinical trial for COVID-19 treatments. WHO. Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments 2020 Jul 06; Accessed: July 6, 2020.
  10. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. US Food & Drug Administration. 2020. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or.
  11. Clinical management protocol: COVD-19. Government of India Ministry of Health and Family Welfare Directorate General of Health Services. Updated 3rd July 2020. Available at: https://www.mohfw.gov.in/pdf/UpdatedClinicalManagementProtocolforCOVID19dated03072020.pdf (accessed on 21st September 2020).
  12. Ministry of Health & Family Welfare. The Gazatte of India: Extraordinary. 2020. Jun, 6, pp. 1–22. Available from: https://cdscogovin/opencms/opencms/en/Notifications/Gazette-Notifications/ (accessed on 21st September 2020).
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.